Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
ACADIA Pharmaceuticals's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 46.07.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. ACADIA Pharmaceuticals's liquidation value for the
three
months ended in Mar. 2026 was MXN11,029 Mil.
ACADIA Pharmaceuticals (MEX:ACAD) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
ACADIA Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACADIA Pharmaceuticals Change In Receivables Related Terms
ACADIA Pharmaceuticals Change In Receivables Historical Data
* Premium members only.
The historical data trend for ACADIA Pharmaceuticals's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACADIA Pharmaceuticals Change In Receivables Chart
ACADIA Pharmaceuticals Change In Receivables Calculation
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-636 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Receivables of MXN-636 Mil mean?
ACADIA Pharmaceuticals (MEX:ACAD) has a Change In Receivables of MXN-636 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for ACADIA Pharmaceuticals and its competitors.
Is ACADIA Pharmaceuticals' Change In Receivables too high?
ACADIA Pharmaceuticals' current Change In Receivables is MXN-636 Mil. Overall, ACADIA Pharmaceuticals has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' Change In Receivables compare to VKTX and EWTX?
ACADIA Pharmaceuticals' Change In Receivables of MXN-636 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for ACADIA Pharmaceuticals and its competitors. ACADIA Pharmaceuticals's current Change In Receivables is MXN-636 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (MEX:ACAD) is currently considered Fairly Valued. The stock's GF Value™ is MXN462.88, compared to a current price of MXN453.75 — trading 2% below its estimated fair value. The current Change In Receivables is MXN-636 Mil. ACADIA Pharmaceuticals' overall GF Score™ is 74/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For ACADIA Pharmaceuticals (MEX:ACAD), the current Change In Receivables is MXN-636 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACADIA Pharmaceuticals (MEX:ACAD) Overvalued in 2026?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be undervalued.
The current stock price of MXN453.75 is trading 2% below its estimated GF Value™ of MXN462.88.
GuruFocus considers ACADIA Pharmaceuticals to be Fairly Valued.
Key valuation signals for MEX:ACAD:
Change In Receivables: MXN-636 Mil
GF Value™: MXN462.88 vs. price of MXN453.75 (2% below fair value)
No single metric tells the full story. See the MEX:ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
74GF Score
Get the complete analysis for MEX:ACAD
Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ACAD has been successfully added to your 
